Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial.

Saved in:
Bibliographic Details
Title: Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial.
Authors: Bergmann L; Medical Clinic II, University Hospital Frankfurt, Frankfurt, Germany. Electronic address: l.bergmann@em.uni-frankfurt.de., Albiges L; Institut Gustave Roussy, Paris, France., Ahrens M; Medical Clinic II, University Hospital Frankfurt, Frankfurt, Germany., Gross-Goupil M; Medical Oncology, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France., Boleti E; Royal Free London NHS Foundation Trust, London, UK., Gravis G; Institut Paoli-Calmettes, Department of Medical Oncology, Aix Marseille Univ, INSERM, CNRS, CRCM, Immunity and Cancer Team, Marseille, France., Fléchon A; Centre Léon Bérard, Lyon, France., Grimm MO; Jena University Hospital, Department of Urology and Comprehensive Cancer Center Central Germany, Jena, Germany., Bedke J; Department of Urology, Eberhard Karls University Tübingen, Tübingen, Germany; Department of Urology & Transplantation Surgery, Eva Mayr-Stihl Cancer Center, Klinikum Stuttgart, Stuttgart, Germany., Barthélémy P; Medical Oncology, Institut de Cancérologie Strasbourg Europe, Strasbourg, France., Castellano D; Hospital Universitario, Madrid, Spain., Mellado B; Hospital Clinic de Barcelona, Barcelona, Spain., Ivanyi P; Medical School, Department of Hematology and Oncology, Hanover, Germany., Rottey S; Department of Medical Oncology, Ghent University Hospital, Ghent, Belgium., Flörcken A; Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Hematology, Oncology, and Tumor Immunology, Berlin, Germany., Suarez C; Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Medical Oncology, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Maroto P; Sant Pau Hospital (Hospital de la Santa Creu i Sant Pau), Barcelona, Spain., Grünwald V; Clinic for Urology and Clinic for Medical Oncology, University Hospital, Essen, Germany., Oosting SF; University Medical Centre Groningen, University of Groningen, Groningen, the Netherlands., Kopecky J; Faculty Hospital Hradec Kralove, Hradec Kralove, Czech Republic., Zschäbitz S; University Hospital, NCT Heidelberg, Heidelberg, Germany., Boegemann M; University Hospital Münster, Clinic for Urology, Münster, Germany., Buchler T; Department of Oncology, First Faculty of Medicine, Charles University and Thomayer University Hospital, Prague, Czech Republic., Niegisch G; Department of Urology, Medical Faculty and University Hospital, Heinrich Heine University Düsseldorf, Düsseldorf, Germany., Goebell PJ; Erlangen University Hospital, Department of Urology and Pediatric Urology, Erlangen, Germany., Waddell T; The Christie NHS Foundation Trust, Manchester, UK., Joly F; Centre Régional de Lutte contre le Cancer François Baclesse, Caen, France., Priou F; Hospital Center Departmental De Vendée, La-Roche-sur-Yon, France., Retz M; Rechts der Isar Medical Center, Technical University of Munich, Munich, Germany., Siemer S; Department of Urology, Saarland University, Homburg/Saar, Germany., Zimmermann U; University Medical Center Greifswald, Clinic for Urology, Greifswald, Germany., Deckbar D; Medical Clinic II, University Hospital Frankfurt, Frankfurt, Germany., Burkholder I; Department of Health Sciences, University of Applied Sciences, Fulda, Germany., Hartmann A; Institute of Pathology University Hospital, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany; Comprehensive Cancer Center Erlangen EMN (CCC ER-ERM), Erlangen, Germany., Haanen JB; Netherlands Cancer Institute, Amsterdam, the Netherlands.
Corporate Authors: Interdisciplinary Renal Cell Carcinoma Working Group of the DKG (IAGN)
Source: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2025 Jul; Vol. 36 (7), pp. 796-806. Date of Electronic Publication: 2025 Apr 01.
Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II; Comparative Study
Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1569-8041 (Electronic) Linking ISSN: 09237534 NLM ISO Abbreviation: Ann Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1569-8041
DOI:10.1016/j.annonc.2025.03.016